Dose-Dense ETC in Early BC

Article

A GermanAGO Group multicenter randomizedphase III trial by Volker J. Moebus, MD,et al has confirmed the benefit of dosedense(DD) ETC chemotherapy in highriskearly breast cancer.

SAN ANTONIO–A GermanAGO Group multicenter randomizedphase III trial by Volker J. Moebus, MD,et al has confirmed the benefit of dosedense(DD) ETC chemotherapy in highriskearly breast cancer (abstract 53). The1,284 patients enrolled had ≥ 4 positiveaxillary nodes (median, 8). DD therapycomprised 3 cycles of epirubicin (Ellence)at 150 mg/m2, paclitaxel (Taxol) at 225mg/m2, and cyclophosphamide (C) at2,500 mg/m2 q2wk with G-CSF support.Conventional therapy was 4 cycles of Eand C at standard dosages, followed by 4courses of T (at 175 mg/m2) q3wk. Morethan 80% of patients received theplanned number of cycles of therapy.

In the DD arm, the relapse-free survivalrate was 70%, vs 62% with conventionaltherapy (P = .029). Overall survivalwas 82% with DD therapy vs 77%with conventional dosing (P = .029). Atotal of 182 patients in the DD armrelapsed vs 226 patients on standardtherapy (HR 0.72, P = .00079). No severecardiotoxicity or unusual toxicitiesoccurred.

Related Videos
Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.
The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.
The goal of creating the Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital is to establish a safe space for Hispanic patients, says Claudia Tellez, MD.
Several factors may contribute to the low Hispanic breast cancer population at Northwestern Memorial Hospital, including a lack of resources and a focus on other disease types.
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Hypofractionated radiotherapy yields less financial toxicity than conventionally fractionated radiotherapy in patients with breast cancer who have undergone reconstruction following mastectomy.
Related Content